The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects
- 31 May 1995
- journal article
- clinical trial
- Published by Elsevier BV in Radiotherapy and Oncology
- Vol. 35 (2), 91-99
- https://doi.org/10.1016/0167-8140(95)01538-r
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Progress report of a phase II and a phase III trial with etanidazole (SR-2508): a multicentre european studyRadiotherapy and Oncology, 1991
- Accelerated treatment and radiation myelitisRadiotherapy and Oncology, 1991
- Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 studyInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Does Incomplete Repair Explain the Apparent Failure of the Basic LQ Model to Predict Spinal Cord and Kidney Responses to Low Doses Per Fraction?International Journal of Radiation Biology, 1988
- Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III–IV squamous cancers of the head and neckInternational Journal of Radiation Oncology*Biology*Physics, 1987
- Clinical trials of radiosensitizers: What should we expect?International Journal of Radiation Oncology*Biology*Physics, 1984
- The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer a pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer)International Journal of Radiation Oncology*Biology*Physics, 1982
- Preliminary results in advanced head and neck cancer with radiotherapy by multiple fractions a dayClinical Radiology, 1980
- Radiotherapy by several sessions a dayThe British Journal of Radiology, 1975
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958